EGFR and glioblastoma: ABT-414 was assessed in phase I trials for EGFR-amplified, recurrent GBM (NCT01800695), wherein the most commonly observed TRAEs were reversible and ocular (i.e., blurred vision and dry eye), as is common with the MMAF payload [80,168].